| Oct 15 |
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
|
| Oct 15 |
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday
|
| Oct 15 |
Johnson & Johnson posts Q3 beat; lowers earnings guidance amid M&A impact
|
| Oct 15 |
Johnson & Johnson 2024 Q3 - Results - Earnings Call Presentation
|
| Oct 15 |
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
|
| Oct 15 |
J&J Reports Strong Earnings but Talc Worries Remain. The Stock Falls.
|
| Oct 15 |
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
|
| Oct 15 |
Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
|
| Oct 15 |
Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates
|
| Oct 15 |
Zenith Values Caution Wall Street Pre-Bell; Asia Mixed, Europe Off
|
